IMW 2021 | CCR10 as a potential target in myeloma
Arun Wiita, PhD, of the University of California, San Francisco, CA, talks on C-C motif chemokine receptor 10 (CCR10) as a potential new immunotherapeutic target for the treatment of multiple myeloma. Using cell surface proteomics and mass spectrometry, it was found that CCR10 is highly expressed by plasma cells, expressed at low levels by some T-cells, and highly expressed by regulatory T-cells. Dr Wiita describes how CCR10 could be targeted on plasma cells and regulatory T-cells to achieve therapeutic benefits for patients with myeloma. So far, Dr Wiita’s team has developed an investigative chimeric antigen receptor (CAR) T-cell that targets CCR10 by acting on its natural ligand CCL27. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Arun Wiita, PhD, is an equity holder and scientific advisory board member for Indapta Therapeutics, LLC, and Protocol Intelligence, LLC.
